News

This analysis of clinical and genomic data from 1662 patients with advanced cancer who were treated with immune checkpoint inhibitors (ICI) and 5371 patients who did not receive ICI was designed to investigate if tumor mutational burden (TMB) predicts clinical response to ICI. Higher TMB was associated with improved overall survival among all patients; however, […]

Mutations in the KRAS gene are the most common driver oncogenes present in lung adenocarcinomas. We analyzed the largest multi-institutional database available containing patients with metastatic KRAS mutant lung adenocarcinomas. In the LCMC study, 27% of lung adenocarcinomas patients harbored a KRAS mutation and up to third of them had another oncogenic driver. Patients with

The androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60-80% of breast cancers, with higher prevalence among estrogen receptor-positive (ER+) tumors. Androgen treatment inhibits ER signaling in ER+/AR+ breast cancer cell lines, and AR expression is associated with improved survival for this subtype in epidemiologic

In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free survival (PFS) versus standard-of-care (SoC) EGFR-TKI (gefitinib or erlotinib), in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced NSCLC. Interim overall survival data were encouraging but not formally statistically significant at

The revised 2017 European LeukemiaNet (ELN) classification (ELN-2017) of acute myeloid leukemia (AML) divides patients into 3 prognostic risk categories, with additional factors such as the fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) allele ratio (AR) considered for risk stratification. To the best of the authors’ knowledge, the prognostic usefulness of ELN-2017 in comparison

Despite the clinical advantage of the combination of trastuzumab and platinum-based chemotherapy in HER2-amplified tumors, resistance will eventually develop. The identification of molecular mechanisms related to primary and acquired resistance is needed. We generated lapatinib- and trastuzumab-resistant clones deriving from two different HER2-amplified gastric cancer cell lines. Molecular changes such as protein expression and gene-expression

MGMT protein expression has been shown to be an independent prognostic biomarker of newly diagnosed glioblastomas. The immunohistochemistry test may identify, upfront and at lower cost, patients who may not respond to the Stupp protocol. This finding of a retrospective analysis was reported at the 60th Annual Meeting of the American Society for Radiation Oncology

BRAFV600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibitor of BRAFV600, in patients with gliomas that harbor this mutation. Vemurafenib demonstrated evidence of durable antitumor activity in some patients with BRAFV600-mutant gliomas,

This study retrospectively evaluated whether tumor expression of PD-L1 could predict the response of EGFR-mutated NSCLC to EGFR TKI therapy in 101 patients. Strong PD-L1 expression significantly decreased the objective response rate compared with weak or negative PD-L1 expression (35.7% vs 63.2% vs 67.3%; P = .002) and shortened progression-free survival (3.8 vs 6.0 vs

This pooled analysis was designed to evaluate the correlation between extent of ALK FISH positivity and efficacy of crizotinib among patients with non–small cell lung cancer. ALK-positivity above 15% was associated with crizotinib response. In clinical trials of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) treated with crizotinib, evaluation of the relationship